All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people who underwent a lower limb revascularisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people who underwent a lower limb revascularisation
Duplex ultrasound plus pulse palpation and arterial pressure index… showed no clear difference in all‐cause mortality compared with pulse palpation plus arterial pressure index (ABI or TBI) (short term) (low certainty).
1 finding from 1 review
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · atherosclerotic cardiovascular disease
EDTA showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · peripheral arterial disease
Gene therapy showed no clear difference in all‐cause mortality compared with no gene therapy control (moderate certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux showed no clear difference in all‐cause mortality compared with idraparinux (low certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in all‐cause mortality compared with standard therapy (low certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality1 · people with unprovoked VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality1 · people with unprovoked VTE
Standard testing plus PET/CT scanning showed no clear difference in all‐cause mortality1 compared with standard testing alone (moderate certainty).
1 finding from 1 review
All‐cause mortalitye · patients with unprovoked venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found